Background Psoriasis is an immune‐mediated disease with either skin or joints
manifestations, or both, and it has a major impact on quality of life. Although there is …

Psoriasis is a common, chronic, inflammatory, multisystem disease with predominantly skin
and joint manifestations affecting approximately 2% of the population. In the first 5 parts of …

European S3-Guidelines on the systemic treatment of psoriasis vulgaris D Pathirana, AD
Ormerod, P Saiag, C Smith, PI Spuls, A Na Page 1 JEADV october 2009, volume 23 …

Psoriasis vulgaris is a common and often chronic inflammatory skin disease. The incidence
of psoriasis in Western industrialized countries ranges from 1.5% to 2%. Patients afflicted …

Management of psoriasis begins with identification of the extent of cutaneous disease.
However, a holistic, contractual approach to treatment is encouraged, with particular …

Calcium is vital to many biologic processes. In skin, it has a profound effect on keratinocyte
proliferation, differentiation, and cell-cell adhesion. Serum calcium is tightly regulated by …

In patients with moderate-to-severe psoriasis, remission can be difficult to achieve and
sustain. Both acutely acting and long-term maintenance agents are needed. Speed and …

Background There is limited information on systemic and biological treatment optimization
and transitioning in routine clinical practice. Objective To provide practical guidance on …

Cyclosporine is a calcineurin inhibitor that acts selectively on T cells. It has been used in
dermatology since 1997 for its US Food and Drug Administration indication of psoriasis and …

Psoriasis is a chronic, immune‐mediated disorder that usually requires long‐term treatment
for control. Approximately 25% of patients have moderate to severe disease and require …